# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7427055

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
JIANWEI YU	11/02/2020

### **RECEIVING PARTY DATA**

Name:	SPES PHARMACEUTICALS INC.
Street Address:	675 US HIGHWAY 1, SUITE 118
City:	NORTH BRUNSWICK
State/Country:	NEW JERSEY
Postal Code:	08902

## **PROPERTY NUMBERS Total: 3**

Property Type	Number
Application Number:	63108509
PCT Number:	US2021057556
Application Number:	17516400

### **CORRESPONDENCE DATA**

**Fax Number:** (703)816-4100

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 703-816-4000

Email: jck@nixonvan.com

Correspondent Name: XIAOXIANG LIU

Address Line 1: 901 NORTH GLEBE ROAD, 11TH FLOOR

Address Line 2: NIXON & VANDERHYE P.C.

Address Line 4: ARLINGTON, VIRGINIA 22203-1808

ATTORNEY DOCKET NUMBER: SL-8547-0002

NAME OF SUBMITTER: XIAOXIANG LIU, REG. NO. 63,566

SIGNATURE: /Xiaoxiang Liu/

DATE SIGNED: 07/12/2022

**Total Attachments: 2** 

source=8547\_0002\_Assignment#page1.tif source=8547\_0002\_Assignment#page2.tif

PATENT 507380130 REEL: 060483 FRAME: 0213

#### ASSIGNMENT

In consideration of the sum of one dollar (\$1.00) or equivalent and other good and valuable consideration paid to the undersigned inventor: **Jianwei YU** hereby sells and assigns to **Spes Pharmaceuticals Inc.**, whose mailing address is 675 US Highway 1, Suite 118, North Brunswick, NJ 08902 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

- (a) in the invention(s) known as **AQUEOUS COMPOSITIONS OF BORTEZOMIB** for which a provisional application for patent in the United States of America was filed on November 2, 2020 (also known as United States Application No. 63/108,509), in any and all non-provisional applications therefrom, in any and all Letters Patent(s) granted from such non-provisional applications, and
- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the inventor had this assignment and sale not been made.

The undersigned inventor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient and further to perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

3048902

PATENT REEL: 060483 FRAME: 0214 The undersigned inventor agrees to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 23117** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventor hereby represents that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 23117** are the legal representatives of, and attorneys for, the assignee, and are <u>NOT</u> the legal representatives of, and attorneys for, the inventor.

In witness whereof, executed by the undersigned inventor on the date opposite his/her name.

Date:	Nov. 02, 2020	Signature of Inventor:	
		Jianwei YU	

SIGNED on behalf of the said ASSIGNEE.

Page 2 of 2

3048902